BSE Live
Sep 15, 16:01Prev. Close
1094.60
Open Price
1085.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 15, 15:59Prev. Close
1094.40
Open Price
1090.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
Net Profit/Loss Before Extraordinary Items And Tax | 2,358.45 | 2,402.92 | 1,614.35 | 1,637.48 | 4,193.01 | |
Net CashFlow From Operating Activities | 1,645.79 | 1,714.80 | 1,821.16 | 3,726.71 | 2,994.41 | |
Net Cash Used In Investing Activities | -2,065.90 | -159.96 | -3,459.68 | -1,613.51 | -2,648.73 | |
Net Cash Used From Financing Activities | 616.31 | -1,837.03 | 1,719.48 | -2,447.54 | -27.94 | |
Foreign Exchange Gains / Losses | 15.74 | 8.38 | 0.48 | -1.03 | -1.51 | |
Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Inc/Dec In Cash And Cash Equivalents | 211.94 | -273.81 | 81.44 | -335.37 | 316.23 | |
Cash And Cash Equivalents Begin of Year | 83.32 | 357.13 | 48.21 | 383.58 | 67.35 | |
Cash And Cash Equivalents End Of Year | 295.26 | 83.32 | 129.65 | 48.21 | 383.58 |
11.09.2025
Aurobindo Pharma shares rise 4.5% as report says GTCR strikes $4.8-bn deal to buy Zentiva
08.09.2025
Aurobindo Pharma shares fall on eight observations from USFDA
08.09.2025
01.09.2025
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
27.05.2025
Aurobindo Pharm Standalone March 2025 Net Sales at Rs 2,731.99 crore, down 5.6% Y-o-Y
12.02.2025
Aurobindo Pharm Standalone December 2024 Net Sales at Rs 2,916.63 crore, up 8.34% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL